JP2017516835A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017516835A5 JP2017516835A5 JP2016571284A JP2016571284A JP2017516835A5 JP 2017516835 A5 JP2017516835 A5 JP 2017516835A5 JP 2016571284 A JP2016571284 A JP 2016571284A JP 2016571284 A JP2016571284 A JP 2016571284A JP 2017516835 A5 JP2017516835 A5 JP 2017516835A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- compound according
- substituted
- hydrogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 21
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 208000006289 Rett Syndrome Diseases 0.000 claims description 6
- -1 (S) -4-amino-2-hydroxybutyryl Chemical group 0.000 claims description 5
- 108020004485 Nonsense Codon Proteins 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 101150083522 MECP2 gene Proteins 0.000 claims description 4
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000037434 nonsense mutation Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 125000000753 cycloalkyl group Chemical group 0.000 description 8
- 239000005022 packaging material Substances 0.000 description 2
- UXWAYRJKFWINEC-DSVJDYJBSA-N CC([C@H](C(C1O)O)O[C@H]1OC(C([C@@H](CC1N)N)O)[C@@H]1OC(CC([C@](C1)([C@@]1(C)O)O)O)(CN)O)S(=C)#[N-2] Chemical compound CC([C@H](C(C1O)O)O[C@H]1OC(C([C@@H](CC1N)N)O)[C@@H]1OC(CC([C@](C1)([C@@]1(C)O)O)O)(CN)O)S(=C)#[N-2] UXWAYRJKFWINEC-DSVJDYJBSA-N 0.000 description 1
- ZYSQPTHMPAJRAR-MRWISRKKSA-N CC([C@H](C(C1O)O)O[C@H]1OC(C([C@@H](CC1N)N)O)[C@@H]1O[C@H](C(C1O)N)OC(CO)[C@H]1O)=S=C Chemical compound CC([C@H](C(C1O)O)O[C@H]1OC(C([C@@H](CC1N)N)O)[C@@H]1O[C@H](C(C1O)N)OC(CO)[C@H]1O)=S=C ZYSQPTHMPAJRAR-MRWISRKKSA-N 0.000 description 1
- 0 C[C@](C([C@](C(C1N)O)O)O[C@@]1O[C@@](C(C[C@](C1O)N*)N)C1O[C@@](C(C1O)O)O[C@]1C(C)=S=C)O Chemical compound C[C@](C([C@](C(C1N)O)O)O[C@@]1O[C@@](C(C[C@](C1O)N*)N)C1O[C@@](C(C1O)O)O[C@]1C(C)=S=C)O 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462008028P | 2014-06-05 | 2014-06-05 | |
| US62/008,028 | 2014-06-05 | ||
| PCT/IL2015/050573 WO2015186134A1 (en) | 2014-06-05 | 2015-06-04 | Use of aminoglycoside analogs in the treatment of rett syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017516835A JP2017516835A (ja) | 2017-06-22 |
| JP2017516835A5 true JP2017516835A5 (enExample) | 2018-04-26 |
Family
ID=53525222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571284A Pending JP2017516835A (ja) | 2014-06-05 | 2015-06-04 | レット症候群治療におけるアミノグリコシド類縁体の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20170360817A1 (enExample) |
| EP (1) | EP3151840A1 (enExample) |
| JP (1) | JP2017516835A (enExample) |
| CA (1) | CA2949754A1 (enExample) |
| IL (1) | IL249402A0 (enExample) |
| WO (1) | WO2015186134A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2640734T (lt) | 2010-11-18 | 2018-02-12 | Technion Research & Development Foundation Ltd. | Aminoglikozidai ir jų panaudojimas genetinių susirgimų gydymui |
| EP3151840A1 (en) | 2014-06-05 | 2017-04-12 | Eloxx Pharmaceuticals Ltd. | Use of aminoglycoside analogs in the treatment of rett syndrome |
| WO2017037718A1 (en) | 2015-09-02 | 2017-03-09 | Eloxx Pharmaceuticals Ltd. | Aminoglycoside derivatives and uses thereof in treating genetic disorders |
| CA2996763A1 (en) * | 2015-09-02 | 2017-03-09 | Eloxx Pharmaceuticals Ltd. | Aminoglycoside derivatives and uses thereof in treating genetic disorders |
| WO2017037717A1 (en) | 2015-09-02 | 2017-03-09 | Eloxx Pharmaceuticals Ltd. | Aminoglycoside derivatives and uses thereof in treating genetic disorders |
| AU2018235441C1 (en) * | 2017-03-15 | 2024-10-24 | Eloxx Pharmaceuticals Ltd. | Large scale preparation of pseudo-trisaccharide aminoglycosides and of intermediates thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5960712A (ja) | 1982-09-30 | 1984-04-06 | Toshiba Corp | デ−タ判別装置 |
| JP5830213B2 (ja) * | 2004-02-17 | 2015-12-09 | ザ ホスピタル フォー シック チルドレン | Ｍｅｃｐ２ｅ１遺伝子 |
| DK2390255T3 (en) * | 2006-04-03 | 2016-11-07 | Technion Res & Dev Foundation | Novel aminoglycosides and uses thereof in the treatment of genetic disorders |
| LT2640734T (lt) | 2010-11-18 | 2018-02-12 | Technion Research & Development Foundation Ltd. | Aminoglikozidai ir jų panaudojimas genetinių susirgimų gydymui |
| EP3151840A1 (en) | 2014-06-05 | 2017-04-12 | Eloxx Pharmaceuticals Ltd. | Use of aminoglycoside analogs in the treatment of rett syndrome |
-
2015
- 2015-06-04 EP EP15735743.5A patent/EP3151840A1/en not_active Withdrawn
- 2015-06-04 WO PCT/IL2015/050573 patent/WO2015186134A1/en not_active Ceased
- 2015-06-04 US US15/316,209 patent/US20170360817A1/en not_active Abandoned
- 2015-06-04 JP JP2016571284A patent/JP2017516835A/ja active Pending
- 2015-06-04 CA CA2949754A patent/CA2949754A1/en not_active Abandoned
-
2016
- 2016-12-05 IL IL249402A patent/IL249402A0/en unknown
-
2019
- 2019-01-28 US US16/258,735 patent/US10576095B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020097577A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2016106149A5 (enExample) | ||
| JP2015078230A5 (enExample) | ||
| JP2016515628A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2013518107A5 (enExample) | ||
| JP2016513130A5 (enExample) | ||
| JP2016034978A5 (enExample) | ||
| JP2016531871A5 (enExample) | ||
| JP2014506907A5 (enExample) | ||
| JP2019515908A5 (enExample) | ||
| JP2015502926A5 (enExample) | ||
| JP2016539157A5 (enExample) | ||
| JP2018524306A5 (enExample) | ||
| JP2016537432A5 (enExample) | ||
| MY193740A (en) | "substituted 2,4 diamino-quinoline as new anticancer agents" | |
| PH12015501945A1 (en) | Formulations of organic compounds | |
| JP2016515550A5 (enExample) | ||
| JP2019507764A5 (enExample) | ||
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| JP2013542981A5 (enExample) | ||
| JP2014148552A5 (enExample) | ||
| JP2015522592A5 (enExample) | ||
| EA201792237A1 (ru) | Фармацевтические составы |